Charles River Laboratories Intl. Inc (NYSE:CRL) Insider Sells $162,819.64 in Stock

Charles River Laboratories Intl. Inc (NYSE:CRL) insider David Ross Smith sold 1,249 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the sale, the insider now directly owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of CRL traded up $0.99 during trading hours on Tuesday, reaching $130.82. 210,684 shares of the company traded hands, compared to its average volume of 375,249. The firm has a fifty day moving average price of $137.18. The stock has a market cap of $6.47 billion, a P/E ratio of 21.69, a price-to-earnings-growth ratio of 1.69 and a beta of 1.10. The company has a debt-to-equity ratio of 1.47, a current ratio of 1.59 and a quick ratio of 1.38. Charles River Laboratories Intl. Inc has a 12 month low of $103.00 and a 12 month high of $149.07.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.55 by $0.08. The firm had revenue of $657.60 million for the quarter, compared to analyst estimates of $662.61 million. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.62 EPS. Equities analysts anticipate that Charles River Laboratories Intl. Inc will post 6.53 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in CRL. Tompkins Financial Corp boosted its stake in shares of Charles River Laboratories Intl. by 63.1% during the 1st quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 77 shares in the last quarter. Flagship Harbor Advisors LLC lifted its position in Charles River Laboratories Intl. by 132.1% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 181 shares during the period. Financial Gravity Wealth Inc. purchased a new position in Charles River Laboratories Intl. during the 1st quarter valued at about $59,000. CWM LLC lifted its position in Charles River Laboratories Intl. by 156.9% during the 1st quarter. CWM LLC now owns 429 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 262 shares during the period. Finally, Steward Partners Investment Advisory LLC purchased a new position in Charles River Laboratories Intl. during the 2nd quarter valued at about $69,000. 94.33% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have issued reports on CRL. Svb Leerink began coverage on shares of Charles River Laboratories Intl. in a report on Monday, June 10th. They issued an “outperform” rating and a $155.00 price target on the stock. Zacks Investment Research lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Leerink Swann began coverage on shares of Charles River Laboratories Intl. in a report on Monday, June 10th. They issued an “outperform” rating on the stock. Evercore ISI reissued an “outperform” rating and issued a $160.00 price target on shares of Charles River Laboratories Intl. in a report on Tuesday, April 30th. Finally, ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and an average price target of $147.29.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: What is the operating income formula?

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.